Dr. Brett E. Fortune, M.D.
Hepatology (Hepatology Physician)
- Medicare participating
At a glance
- Medical school
- Wake Forest University School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 90
Licensed in Connecticut since 2012, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Wake Forest University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hepatology Physician primary
NY license 283730 -
Gastroenterology Physician
CT license 051154 (first issued 2012; active) -
Internal Medicine Physician
OH license 35088963 -
Transplant Hepatology Physician
FL license ME177299
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Montefiore Medical Center Bronx, NY
- Jackson Health System Miami, FL
Medical groups
- Montefiore Medical Center (2,820 clinicians)
- Public Health Trust of Miami Dade County Florida (457 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 188
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 18 | 16 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 16 |
| Measurement of liver stiffness | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ursodiol Other prescribers in Miami, FL | 35 |
| Carvedilol Other prescribers in Miami, FL | 26 |
| Tenofovir Disoproxil Fumarate | 22 |
| Spironolactone Other prescribers in Miami, FL | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 45 payments worth $56,594 in total to this clinician.
| Novo Nordisk Inc | $27,091 |
|---|---|
| Madrigal Pharmaceuticals | $14,635 |
| W. L. Gore & Associates, Inc. | $6,180 |
| Bard Peripheral Vascular, Inc. | $4,031 |
| Bausch Health US, LLC | $3,654 |
| Gilead Sciences, Inc. | $717 |
| Mallinckrodt Hospital Products Inc. | $142 |
| Mirum Pharmaceuticals, Inc. | $95.43 |
| Compensation for services other than consulting (speaking, faculty) | $37,891 |
|---|---|
| Consulting Fee | $14,073 |
| Food and Beverage | $2,472 |
| Travel and Lodging | $2,158 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $9,616 |
| Novo Nordisk Inc Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $9,224 |
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $5,505 |
| Madrigal Pharmaceuticals Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,515 |
| Madrigal Pharmaceuticals Feb 11, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,548 |
| Madrigal Pharmaceuticals Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,548 |
| Bausch Health US, LLC May 8, 2025 | Consulting Fee | $3,200 |
| Bard Peripheral Vascular, Inc. Mar 6, 2025 | Consulting Fee | $2,275 |
| Madrigal Pharmaceuticals Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,935 |
| W. L. Gore & Associates, Inc. Feb 28, 2025 | Consulting Fee VIATORR Endoprosthesis · Devices | $1,770 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $9,224 |
| Novo Nordisk Inc Dec 17, 2025 | Travel and Lodging Wegovy · Obesity · travel to Melbourne, FL · in-kind | $1,123 |
| Novo Nordisk Inc Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $9,616 |
| Novo Nordisk Inc Dec 4, 2025 | Travel and Lodging Wegovy · Obesity · travel to Hollywood, FL · in-kind | $751 |
| Bard Peripheral Vascular, Inc. Nov 24, 2025 | Consulting Fee | $1,625 |
| Novo Nordisk Inc Nov 3, 2025 | Consulting Fee Multiple Therapeutic Areas | $393 |
| W. L. Gore & Associates, Inc. Oct 17, 2025 | Consulting Fee GORE VIATORR TIPS Endoprosthesis · Devices | $660 |
| W. L. Gore & Associates, Inc. Oct 17, 2025 | Consulting Fee GORE VIATORR TIPS Endoprosthesis · Devices | $330 |
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $5,505 |
| Madrigal Pharmaceuticals Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,935 |
| W. L. Gore & Associates, Inc. Jul 7, 2025 | Consulting Fee GORE VIATORR TIPS Endoprosthesis with Controlled Expansion · Devices | $1,650 |
| Bausch Health US, LLC May 9, 2025 | Consulting Fee | $400 |
| Bausch Health US, LLC May 8, 2025 | Consulting Fee | $3,200 |
| Madrigal Pharmaceuticals Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,548 |
| Madrigal Pharmaceuticals Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,515 |
| Bard Peripheral Vascular, Inc. Mar 6, 2025 | Consulting Fee | $2,275 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026684;GTF;11431757 | $284 |
| W. L. Gore & Associates, Inc. Feb 28, 2025 | Consulting Fee VIATORR Endoprosthesis · Devices | $1,770 |
| W. L. Gore & Associates, Inc. Feb 28, 2025 | Consulting Fee VIATORR Endoprosthesis · Devices | $1,770 |
| Madrigal Pharmaceuticals Feb 11, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,548 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $69,195 in research payments for these studies, mostly to the institutions running them.
- A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and …
AstraZeneca Pharmaceuticals LP - Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132)
Bausch Health US, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.